Tumors derived from antigen presenting cells

Semin Immunol. 1996 Oct;8(5):281-7. doi: 10.1006/smim.1996.0036.

Abstract

Vaccine strategies aimed at enhancing the processing of tumor antigens by activated 'professional' antigen presenting cells (APCs) can sometimes result in the generation of systemic T-cell mediated anti-tumor immune responses capable of eradicating a micrometastatic tumor burden. This observation raises the interesting question of why certain tumors such as B-cell lymphomas or myeloid leukemias--malignancies in lineages normally characterized by potent APC capacity--fail to be eliminated by host T-cell responses. Potentially unique aspects of the immune response to such hematopoietic cancers are discussed in the context of the current understanding of factors regulating T-cell activation and tolerance. These considerations may have relevance for the application of cancer immunotherapy to this class of diseases.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigen-Presenting Cells / pathology*
  • Humans
  • Neoplasms / etiology*
  • Neoplasms / immunology*
  • Neoplasms, Experimental / etiology*
  • Neoplasms, Experimental / immunology*